Novartis' Jakavi drug wins EU green light for wider use
Novartis said on Friday its drug Jakavi has been recommended by European health regulators for wider use, boosting the sales prospects for the medicine.
European Medicines Agency (EMA) experts recommended that Jakavi -- which is already approved to treat myelofibrosis, a form of blood cancer -- be given the green light as a treatment for polycythemia vera, a chronic incurable blood
By Reuters
January 23, 2015
Novartis said on Friday its drug Jakavi has been recommended by European health regulators for wider use, boosting the sales prospects for the medicine.
European Medicines Agency (EMA) experts recommended that Jakavi -- which is already approved to treat myelofibrosis, a form of blood cancer -- be given the green light as a treatment for polycythemia vera, a chronic incurable blood cancer.
Recommendations for marketing approval by the agency's Committee for Medicinal Products for Human Use (CHMP) are normally endorsed by the European Commission within a couple of months.
European Medicines Agency (EMA) experts recommended that Jakavi -- which is already approved to treat myelofibrosis, a form of blood cancer -- be given the green light as a treatment for polycythemia vera, a chronic incurable blood cancer.
Recommendations for marketing approval by the agency's Committee for Medicinal Products for Human Use (CHMP) are normally endorsed by the European Commission within a couple of months.
-
Pink reveals health routine for asthma management -
Gigi Hadid talks about 'relieving tension' amid having Hashimoto's disease -
Selena Gomez explains why she thought lupus was 'life-or-death' -
How Kim Kardashian made her psoriasis ‘almost’ disappear -
Nick Jonas gets candid about his type 1 diabetes diagnosis -
Sir Jackie Stewart’s son advocates for dementia patients -
5 celebrities you didn't know have experienced depression -
Late James Van Der Beek inspires bowel cancer awareness post death